[1]孙来顺.精神分裂症的药物治疗[J].医学信息,2021,34(21):42-45.[doi:10.3969/j.issn.1006-1959.2021.21.010]
　SUN Lai-shun.Drug Treatment of Schizophrenia[J].Medical Information,2021,34(21):42-45.[doi:10.3969/j.issn.1006-1959.2021.21.010]
点击复制

精神分裂症的药物治疗()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
34卷
期数:
2021年21期
页码:
42-45
栏目:
综述
出版日期:
2021-11-01

文章信息/Info

Title:
Drug Treatment of Schizophrenia
文章编号:
1006-1959（2021）21-0042-04
作者:
孙来顺
（天津市宝坻区安康医院精神科，天津 301800）
Author(s):
SUN Lai-shun
(Department of Psychiatry,Ankang Hospital,Baodi District,Tianjin 301800,China)
关键词:
精神分裂症; 抗精神病药物; 阿立哌唑
Keywords:
Schizophrenia; Antipsychotic drugs; Aripiprazole
分类号:
R749.3
DOI:
10.3969/j.issn.1006-1959.2021.21.010
文献标志码:
A
摘要:
精神分裂症是临床最常见的精神疾病之一，具有病情迁延、反复发作、致残率高的特征。目前，主要采用药物治疗，以控制病情，改善患者临床症状。由于对精神分裂症的发病机制尚未完全明确，临床仍然缺乏特效的治疗药物，主要遵循早期、有效和维持原则，即尽早治疗、单药治疗、原药治疗及个体化治疗，以改善患者预后。随着相关药物的研究进展，可供选择的治疗药物种类越来越多，科学合理是当前临床迫切需要解决的问题。本文从精神分裂症药物治疗原则、不同时期和难治性精神分裂症药物治疗的选择进行综述，并着重阐述以阳性症状为主的患者、以阴性症状为主患者及伴抑郁存在自杀和自伤倾向患者的药物治疗，以期为该病的药物治疗提供理论参考。
Abstract:
Schizophrenia is one of the most common mental diseases in clinic, with the characteristics of prolonged illness, recurrent attacks and high disability rate. At present, drug therapy is mainly used to control the disease and improve the clinical symptoms of patients. Since the pathogenesis of schizophrenia has not been fully clarified, there is still a lack of specific therapeutic drugs in clinic, which mainly follows the principles of early, effective and maintenance to improve the prognosis of patients, that is, early treatment, single drug treatment, technical drug treatment and individualized treatment. With the research progress of related drugs, there are more and more kinds of therapeutic drugs available, scientific and reasonable is an urgent problem to be solved in clinical practice. This article reviews the principles of drug treatment for schizophrenia, the selection of drug treatment for different periods and refractory schizophrenia, and focus on the drug treatment of patients with positive symptoms, patients with negative symptoms and patients with suicidal and self injury tendency with depression, in order to provide theoretical reference for drug treatment of the disease.

参考文献/References:

[1]程伟.阿立哌唑联合利培酮治疗难治性精神分裂症临床对照研究[J].中国药业,2017,26(7):59-61.[2]谢耀春.利培酮和奥氮平治疗难治性精神分裂症的疗效与安全性[J].临床合理用药杂志,2016,9(20):55-56.[3]中华医学会精神病学分会.精神分裂症防治指南[M].北京:北京大学医学出版社,2015:5.[4]龙茂远,韦伟香,黄江,等.利培酮治疗难治性精神分裂症的效果[J].医药卫生(全文版),2019,1(1):61.[5]彭国胜.利培酮和奥氮平在难治性精神分裂症患者治疗中的应用效果对比分析[J].当代医学,2018,24(13):106-107.[6]伏彩霞,马雪红,尚天明,等.奥氮平治疗难治性精神分裂症的疗效观察[J].世界中医药,2017,12(S1):341-342.[7]杨相勇,苏靖,高珊珊.利培酮对精神分裂症首次发病患者认知功能的影响研究[J].中国医药指南,2017,15(30):1.[8]汪春运.抗精神病药的全程治疗[J].中国康复理论与实践,2004,10(4):207-209. [9]朱文静,陈致宇,朱丞,等.经典与非经典抗精神病药对精神分裂症患者社会功能影响的5年随访[J].临床精神医学杂志,2017,27(1):32-34.[10]江开达.精神分裂症长期治疗对复发的影响[J].中华精神科杂志,2018,51(1):69-70. [11]Haji Seyed Javadi A,Shafikhani AA,Zamir SM,et al.Evaluation of the Effect of Fluvoxamine in Patients With Schizophrenia Under Risperidone Treatment: A Clinical Trial[J].J Clin Psychopharmacol,2018,38(2):119-124.[12]王晓文.阿立哌唑与利培酮治疗难治性精神分裂症的临床疗效分析[J].青海医药杂志,2017,47(12):8-9.[13]张开国,黄燕虹.精神分裂症患者未治疗期及早期干预[J].国际精神病学杂志,2019,46(3):396-399.[14]刘爽,庞羽,李刚.氯普噻吨联合氟哌啶醇治疗难治性精神分裂症的临床研究[J].现代药物与临床,2020,35(8):1562-1565.[15]陈龙涛,范鲁.影响女性精神分裂症患者再入院的多因素临床研究[J].医学信息,2015,28(3):211.[16]廖恒,余姝,黄智,等.阿立哌唑与利培酮治疗难治性精神分裂症的临床疗效对比[J].现代生物医学进展,2016,16(12):2333-2335,2299.[17]金枝,罗继明,王鹤秋.帕利哌酮联合氯氮平治疗难治性精神分裂症的临床研究[J].现代实用医学,2016,28(8):1034-1035.[18]王红英,张云淑,李媛媛,等.氯氮平联合利培酮治疗难治性精神分裂症的临床疗效[J].中国地方病防治杂志,2017,32(8):934,936.[19]向宏宇,张丽.氯氮平辅助利培酮治疗难治性精神分裂症患者的疗效及安全性[J].中国实用医药,2018,13(15):18-20.[20]郝健.氨磺必利与利培酮治疗精神分裂症阴性症状对照研究[J].黑龙江医药,2015,28(5):1077-1078.[21]Jin G,Xu Y,Song Q,et al.Panss, mental condition and inflammatory state of risperidone on schizophrenia[J].Acta Medica Mediterranea,2019,35(2):905-907.[22]陈东营.氯氮平联合齐拉西酮治疗难治性精神分裂症89例疗效分析[J].中国实用医药,2017,12(14):108-109.[23]曾惠英,宋丹杏,伍中坚.氯氮平联合氨磺必利治疗难治性精神分裂症临床效果及安全性分析[J].中国当代医药,2017,24(14):112-114.[24]董会艳．奥氮平联合丙戊酸钠治疗难治性精神分裂症的效果[J]．国际医药卫生导报,2018,24(18):2822－2824.[25]Pillai A,Schooler NR,Peter D,et al.Predicting relapse in schizophrenia: Is BDNF a plausible biological marker?[J].Schizophr Res,2018(193):263-268.[26]夏德新.无抽搐电休克联合氯氮平治疗难治性精神分裂症临床观察[J].中国卫生标准管理,2016,7(17):113-114.[27]梅其一.精神分裂症的药物联合治疗[J].中华精神科杂志,2015,47(3):175-177.[28]续稳稳.利培酮联合阿立哌唑治疗精神分裂症效果观察[J].临床合理用药杂志,2020,13(6):45-46.[29]王志民.齐拉西酮与氯氮平治疗难治性精神分裂症患者疗效的比较观察[J].中国民康医学,2017,29(2):35-26.[30]赵振文,陈广阳,杨宇.喹硫平和利培酮治疗难治性精神分裂症的疗效及用药依从性研究[J].北方药学,2017,14(4):28-29.[31]徐莉,陈连洲,曾德志,等.氨磺必利治疗乙醇所致精神障碍的临床疗效及安全性评价[J].中国临床药理学杂志,2015,10(14):1379-1381.[32]王云,郭素芹,张红梅,等.氨磺必利治疗儿童少年期精神分裂症的疗效分析[J].中国慢性病预防与控制,2016,24(3):225-227.[33]阳中明,张恩.氨磺必利与齐拉西酮治疗女性精神分裂症效果比较[J].山东医药,2015,12(18):94-95[34]路钊,贺静,陈英,等.精神分裂症患者氯氮平血药浓度与血清同型半胱氨酸水平的相关性[J].中国神经精神疾病杂志,2019,45(10):602-606.[35]王俊,杜云红,刘建萍.齐拉西酮片联合氯氮平治疗难治性精神分裂症疗效及对认知功能的影响[J].国际精神病学杂志,2019,46(2):260-262.[36]胡江.帕罗西汀对难治性精神分裂症阴性症状临床研究[J].陕西医学杂志,2019,48(1):108-110.

相似文献/References:

[1]邹超杰,程宇琪.肠道微生物在精神分裂症中的研究进展[J].医学信息,2018,31(02):29.[doi:10.3969/j.issn.1006-1959.2018.02.011]
　ZOU Chao-jie,CHENG Yu-qi.Progress in the Study of Intestinal Microorganism in Schizophrenia[J].Medical Information,2018,31(21):29.[doi:10.3969/j.issn.1006-1959.2018.02.011]
[2]张 健,江 芮.生活技能训练对精神分裂症缓解期患者日常生活能力的影响[J].医学信息,2018,31(03):118.[doi:10.3969/j.issn.1006-1959.2018.03.040]
　ZHANG Jian,JIANG Rui.Effect of Life Skills Training on Daily Living Ability of Patients with Schizophrenia in Remission Staged[J].Medical Information,2018,31(21):118.[doi:10.3969/j.issn.1006-1959.2018.03.040]
[3]沈雪梅.齐拉西酮与奥氮平治疗首发精神分裂症 疗效及糖脂代谢的影响观察[J].医学信息,2018,31(06):130.[doi:10.3969/j.issn.1006-1959.2018.06.044]
　SHEN XUE-mei.The Effect of Ziprasidone and Olanzapine in the Treatment of First Episode Schizophrenia and the Effect of Glycolipid Metabolism[J].Medical Information,2018,31(21):130.[doi:10.3969/j.issn.1006-1959.2018.06.044]
[4]陈功琦,梁道博.利培酮联合舍曲林治疗精神分裂症阴性症状 疗效和安全性的Meta分析[J].医学信息,2018,31(10):65.[doi:10.3969/j.issn.1006-1959.2018.10.020]
　CHEN Gong-qi,LIANG Dao-bo.Meta Analysis of Efficacy and Safety of Risperidone Combined with Sertraline in the Treatment of Schizophrenia with Negative Symptoms[J].Medical Information,2018,31(21):65.[doi:10.3969/j.issn.1006-1959.2018.10.020]
[5]孙来顺.氨磺必利与利培酮对精神分裂症患者内分泌及糖脂代谢的影响[J].医学信息,2022,35(10):137.[doi:10.3969/j.issn.1006-1959.2022.10.033]
　SUN Lai-shun.Effects of Amisulpride and Risperidone on Endocrine And Glucose and Lipid Metabolism in Patients with Schizophrenia[J].Medical Information,2022,35(21):137.[doi:10.3969/j.issn.1006-1959.2022.10.033]
[6]孙占娟.精神分裂症患者的认知康复治疗进展[J].医学信息,2018,31(13):52.[doi:10.3969/j.issn.1006-1959.2018.13.015]
　SUN Zhan-juan.Progress in Cognitive Rehabilitation Therapy of Schizophrenia Patients[J].Medical Information,2018,31(21):52.[doi:10.3969/j.issn.1006-1959.2018.13.015]
[7]吴金丽.阿立哌唑的临床应用[J].医学信息,2018,31(14):42.[doi:10.3969/j.issn.1006-1959.2018.14.014]
　WU Jin-li.Clinical Application of Aripiprazole[J].Medical Information,2018,31(21):42.[doi:10.3969/j.issn.1006-1959.2018.14.014]
[8]宋典雄.激励理论指导下的护理干预对精神分裂症患者的影响[J].医学信息,2018,31(18):166.[doi:10.3969/j.issn.1006-1959.2018.18.054]
　SONG Dian-xiong.The Effect of Nursing Intervention under the Guidance of Motivation Theory on Patients with Schizophrenia[J].Medical Information,2018,31(21):166.[doi:10.3969/j.issn.1006-1959.2018.18.054]
[9]凌 梅,刘静芳.精神分裂症患者研究伙伴的相关研究进展[J].医学信息,2018,31(19):48.[doi:10.3969/j.issn.1006-1959.2018.19.016]
　LING Mei,LIU Jing-fang.Progress in Research on Research Partners in Patients with Schizophrenia[J].Medical Information,2018,31(21):48.[doi:10.3969/j.issn.1006-1959.2018.19.016]
[10]韩佳睿,张 苹,张 媛.迟发性运动障碍与DNA甲基化之间关系的研究进展[J].医学信息,2018,31(20):32.[doi:10.3969/j.issn.1006-1959.2018.20.010]
　HAN Jia-rui,ZHANG Ping,ZHANG Yuan.Advances in Research on the Relationship between Tardive Dyskinesia and DNA Methylation[J].Medical Information,2018,31(21):32.[doi:10.3969/j.issn.1006-1959.2018.20.010]

更新日期/Last Update: 1900-01-01